ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1122

Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease
Abstract Number: 1463

Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria
Abstract Number: 0107

Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil
Abstract Number: 1375

Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis
Abstract Number: 1052

Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey
Abstract Number: 1249

Short-term Variations in Subchondral Tibial Bone Texture of Conventional X-Rays Predicts Knee Osteoarthritis Progression
Abstract Number: 0126

Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
Abstract Number: 0200

Should Independence Play a Role in Assessing Remission in Rheumatoid Arthritis?
Abstract Number: 1908

Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?
Abstract Number: 0916

Should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis
Abstract Number: 0348

Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Abstract Number: 0026

Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage
Abstract Number: 1619

Silent Giant Cell Arteritis in Patients with Polymyalgia Rheumatica: Characteristics and Peculiarities
Abstract Number: 0684

Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)
Abstract Number: 1625

Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].